The table below summarizes the most recent Apellis Pharmaceuticals insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Apellis Pharmaceuticals insider buys are important for investors to follow.

Date	Insider	Price	Amount
11-18-2021 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$40.00 CAGR »	$10,000,000.00 250,000 shares
5-8-2020 Insider Buy	Paul R. Fonteyne Director	$31.81 CAGR »	$159,034.00 5,000 shares
1-13-2020 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$37.00 CAGR »	$19,999,980.00 540,540 shares
8-29-2019 Insider Buy	Timothy Eugene Sullivan Chief Financial Officer	$29.71 CAGR »	$347,629.94 11,699 shares
3-11-2019 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$17.00 CAGR »	$7,499,992.00 441,176 shares
9-21-2018 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$19.48 CAGR »	$1,583,962.53 81,323 shares
9-19-2018 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$18.34 CAGR »	$2,567,124.00 140,000 shares
11-13-2017 Insider Buy	Capital Management, LTD. Hillhouse >10% Owner	$14.00 CAGR »	$19,999,994.00 1,428,571 shares
11-13-2017 Insider Buy	Cormorant Asset Management, LLC >10% Owner	$14.00 CAGR »	$14,999,992.00 1,071,428 shares
11-13-2017 Insider Buy	Venture Investments Ltd Morningside >10% Owner	$14.00 CAGR »	$8,050,000.00 575,000 shares
11-13-2017 Insider Buy	Global Strategic Fund L.P. Venbio II >10% Owner	$14.00 CAGR »	$1,785,210.00 127,515 shares

Also See: Institutional Holders of APLS
Also See: SEC filings

Below we present the annualized performance delivered by Apellis Pharmaceuticals stock since 11-18-2021 (the date of the most recent insider purchase). The performance of the investment from the time Apellis Pharmaceuticals insider buying occurred is the ultimate test of whether insiders were right about APLS being a good buy.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	11/19/2021
End date:	04/30/2024
Start price/share:	$43.93
End price/share:	$44.19
Dividends collected/share:	$0.00
Total return:	0.59%
Average Annual Total Return:	0.24%
Starting investment:	$10,000.00
Ending investment:	$10,058.75
Years:	2.44

Apellis Pharmaceuticals Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Apellis Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding APLS

APLS — Current Quote

Quotes delayed 20 minutes

Free APLS Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

APLS — Performance

Apellis Pharmaceuticals Insider Buying

Apellis Pharmaceuticals Insider Buying | www.HoldingsChannel.com